134 related articles for article (PubMed ID: 17622180)
1. Quantitative structure-activity relationship studies on zinc-containing metalloproteinase inhibitors.
Gupta SP
Chem Rev; 2007 Jul; 107(7):3042-87. PubMed ID: 17622180
[No Abstract] [Full Text] [Related]
2. New beginnings for matrix metalloproteinase inhibitors: identification of high-affinity zinc-binding groups.
Puerta DT; Lewis JA; Cohen SM
J Am Chem Soc; 2004 Jul; 126(27):8388-9. PubMed ID: 15237990
[TBL] [Abstract][Full Text] [Related]
3. A new role for old ligands: discerning chelators for zinc metalloproteinases.
Jacobsen FE; Lewis JA; Cohen SM
J Am Chem Soc; 2006 Mar; 128(10):3156-7. PubMed ID: 16522091
[TBL] [Abstract][Full Text] [Related]
4. Development of a receptor-based 3D-QSAR study for the analysis of MMP2, MMP3, and MMP9 inhibitors.
Tuccinardi T; Nuti E; Ortore G; Rossello A; Avramova SI; Martinelli A
Bioorg Med Chem; 2008 Aug; 16(16):7749-58. PubMed ID: 18640045
[TBL] [Abstract][Full Text] [Related]
5. Docking studies of matrix metalloproteinase inhibitors: zinc parameter optimization to improve the binding free energy prediction.
Hu X; Shelver WH
J Mol Graph Model; 2003 Nov; 22(2):115-26. PubMed ID: 12932782
[TBL] [Abstract][Full Text] [Related]
6. A quantitative structure-activity relationship study on some series of anthranilic acid-based matrix metalloproteinase inhibitors.
Gupta SP; Kumaran S
Bioorg Med Chem; 2005 Sep; 13(18):5454-62. PubMed ID: 15993609
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and SAR of alpha-sulfonylcarboxylic acids as potent matrix metalloproteinase inhibitors.
Zhang YM; Fan X; Xiang B; Chakravarty D; Scannevin R; Burke S; Karnachi P; Rhodes K; Jackson P
Bioorg Med Chem Lett; 2006 Jun; 16(12):3096-100. PubMed ID: 16632358
[TBL] [Abstract][Full Text] [Related]
8. From model complexes to metalloprotein inhibition: a synergistic approach to structure-based drug discovery.
Puerta DT; Schames JR; Henchman RH; McCammon JA; Cohen SM
Angew Chem Int Ed Engl; 2003 Aug; 42(32):3772-4. PubMed ID: 12923840
[No Abstract] [Full Text] [Related]
9. Snapshots of the reaction mechanism of matrix metalloproteinases.
Bertini I; Calderone V; Fragai M; Luchinat C; Maletta M; Yeo KJ
Angew Chem Int Ed Engl; 2006 Dec; 45(47):7952-5. PubMed ID: 17096442
[No Abstract] [Full Text] [Related]
10. In silico study of MMP inhibition.
Rouffet M; Denhez C; Bourguet E; Bohr F; Guillaume D
Org Biomol Chem; 2009 Sep; 7(18):3817-25. PubMed ID: 19707688
[TBL] [Abstract][Full Text] [Related]
11. The design of inhibitors for medicinally relevant metalloproteins.
Jacobsen FE; Lewis JA; Cohen SM
ChemMedChem; 2007 Feb; 2(2):152-71. PubMed ID: 17163561
[TBL] [Abstract][Full Text] [Related]
12. Novel matrix metalloproteinase inhibitors: generation of lead compounds by the in silico fragment-based approach.
Takahashi K; Ikura M; Habashita H; Nishizaki M; Sugiura T; Yamamoto S; Nakatani S; Ogawa K; Ohno H; Nakai H; Toda M
Bioorg Med Chem; 2005 Jul; 13(14):4527-43. PubMed ID: 15908222
[TBL] [Abstract][Full Text] [Related]
13. Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1.
Reiter LA; Robinson RP; McClure KF; Jones CS; Reese MR; Mitchell PG; Otterness IG; Bliven ML; Liras J; Cortina SR; Donahue KM; Eskra JD; Griffiths RJ; Lame ME; Lopez-Anaya A; Martinelli GJ; McGahee SM; Yocum SA; Lopresti-Morrow LL; Tobiassen LM; Vaughn-Bowser ML
Bioorg Med Chem Lett; 2004 Jul; 14(13):3389-95. PubMed ID: 15177439
[TBL] [Abstract][Full Text] [Related]
14. [Design, synthesis and activity evaluation of novel matrix metalloproteinases inhibitors based on the structure of enzyme].
Jia H; Guo YS; Ge YY; Wen H; Yang J; Yang XY; Du GH; Yang GZ
Yao Xue Xue Bao; 2007 Dec; 42(12):1271-81. PubMed ID: 18338640
[TBL] [Abstract][Full Text] [Related]
15. Future challenges facing the development of specific active-site-directed synthetic inhibitors of MMPs.
Cuniasse P; Devel L; Makaritis A; Beau F; Georgiadis D; Matziari M; Yiotakis A; Dive V
Biochimie; 2005; 87(3-4):393-402. PubMed ID: 15781327
[TBL] [Abstract][Full Text] [Related]
16. Ternary ligand-zinc-hydroxamate complexes.
Chiu YH; Gabriel GJ; Canary JW
Inorg Chem; 2005 Jan; 44(1):40-4. PubMed ID: 15627358
[TBL] [Abstract][Full Text] [Related]
17. In situ "click" assembly of small molecule matrix metalloprotease inhibitors containing zinc-chelating groups.
Hu M; Li J; Yao SQ
Org Lett; 2008 Dec; 10(24):5529-31. PubMed ID: 19053720
[TBL] [Abstract][Full Text] [Related]
18. New heteroarylbenzenesulphonamides as matrix metalloproteinase inhibitors.
Delbecq F; Cordonnier G; Pommery N; Barbry D; Hénichart JP
Bioorg Med Chem Lett; 2004 Mar; 14(5):1119-21. PubMed ID: 14980648
[TBL] [Abstract][Full Text] [Related]
19. Cross-linking yield variation of a potent matrix metalloproteinase photoaffinity probe and consequences for functional proteomics.
David A; Steer D; Bregant S; Devel L; Makaritis A; Beau F; Yiotakis A; Dive V
Angew Chem Int Ed Engl; 2007; 46(18):3275-7. PubMed ID: 17387672
[No Abstract] [Full Text] [Related]
20. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases.
Hu J; Van den Steen PE; Sang QX; Opdenakker G
Nat Rev Drug Discov; 2007 Jun; 6(6):480-98. PubMed ID: 17541420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
